Q-omics provides the consensus-scored TCEAL2 profile across patient tissues and cancer cell-line models. TCEAL2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TCEAL2 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, TCEAL2 RNA expression shows 14,975 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where TCEAL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCEAL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCEAL2 survival associations across molecular data types. TCEAL2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCEAL2 RNA expression–survival associations across cancer types. High TCEAL2 expression shows unfavorable associations in BLCA, but favorable associations in MESO, LGG, CESC, BRCA and ACC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TCEAL2 RNA expression.
This table summarizes TCEAL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TCEAL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCEAL2 shows lower tumor expression in KIRC, BLCA, KICH, KIRP, LUAD and COAD. The KIRC box plot shows higher TCEAL2 RNA expression in normal versus tumor tissue (log2 FC = −3.895, t-test p < 0.001).
This table shows molecular features associated with TCEAL2 in patient tissues and cancer cell lines. In patient samples, TCEAL2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TCEAL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LUNG_SCLC.
